Measuring coverage and accuracy of whole-exome sequencing in clinical context. (December 2018)

• Record Type: Journal Article
• Authors: Kong, Sek Won; Lee, In-Hee; Liu, Xuanshi; Hirschhorn, Joel; Mandl, Kenneth
• Is Part Of: Genetics in medicine. Volume 20:Number 12(2018)
• Page Start: 1617
• Page End: 1626
• Publication Date: 2018-12
• Subjects: breadth of coverage -- depth of coverage -- false negatives -- pharmacogenomics -- whole-exome sequencing; Medical genetics -- Periodicals; Genetic disorders -- Periodicals; 616.04205
• DOI: 10.1038/gim.2018.51
• Languages: English
• ISSNs: 1098-3600

Abstract

Abstract Purpose To evaluate the coverage and accuracy of whole-exome sequencing (WES) across vendors. Methods Blood samples from three trios underwent WES at three vendors. Relative performance of the three WES services was measured for breadth and depth of coverage. The false-negative rates (FNRs) were estimated using the segregation pattern within each trio. Results Mean depth of coverage for all genes was 189.0, 124.9, and 38.3 for the three vendor services. Fifty-five of the American College of Medical Genetics and Genomics 56 genes, but only 56 of 63 pharmacogenes, were 100% covered at 10 × in at least one of the nine individuals for all vendors; however, there was substantial interindividual variability. For the two vendors with mean depth of coverage >120 ×, analytic positive predictive values (aPPVs) exceeded 99.1% for single-nucleotide variants and homozygous indels, and sensitivities were 98.9–99.9%; however, heterozygous indels showed lower accuracy and sensitivity. Among the trios, FNRs in the offspring were 0.07–0.62% at well-covered variants concordantly called in both parents. Conclusion The current standard of 120 × coverage for clinical WES may be insufficient for consistent breadth of coverage across the exome. Ordering clinicians and researchers would benefit from vendors' reports that estimate sensitivity and aPPV, including depth of coverage across the exome.